Literature DB >> 8317962

Upper extremity bypass grafting. A 15-year experience.

C L Mesh1, W J McCarthy, W H Pearce, W R Flinn, P K Shireman, J S Yao.   

Abstract

OBJECTIVE: To analyze the perioperative morbidity and mortality, long-term patient survival, and patency characteristics of arterial bypass related to upper extremity ischemia.
DESIGN: This is a retrospective review of sequential patients undergoing upper extremity arterial bypass during a 15-year period at a single tertiary-care teaching hospital. Data are expressed in a 5-year life-table format and interpreted using log-rank analysis. PATIENTS: Seventy-four patients with upper extremity ischemia undergoing arterial bypass, which included 95 separate operations. MAIN OUTCOME MEASURES: Operative morbidity and mortality, life-table survival, life-table bypass graft patency, and limb salvage are reported.
RESULTS: There was no operative mortality, and there was a single major amputation. Survival rate was 86% at 5 years, and overall patency rate was 61.2% at 5 years, with autogenous conduits superior at all sites compared with prosthesis (70.9% vs 37.7%). Secondary operation was inferior to primary bypass (66% vs 48%) and associated with higher morbidity (22% vs 5%). All far distal forearm prosthetic bypass grafts failed within 1 year.
CONCLUSIONS: Primary upper extremity bypass with venous conduit is a safe, durable procedure, after which prolonged patient survival can be expected.

Entities:  

Mesh:

Year:  1993        PMID: 8317962     DOI: 10.1001/archsurg.1993.01420190091012

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  2 in total

1.  REVASCULARIZATION OF THE ISCHEMIC UPPER LIMB.

Authors:  K M Rai; K K Maudar; V Ravishankar; J M Borcar; K S Rao; R S Rajan
Journal:  Med J Armed Forces India       Date:  2017-06-26

2.  True aneurysm of brachial artery.

Authors:  Narcis Hudorović; Ivo Lovričević; Dario Bjorn Franjić; Petar Brkić; Davor Tomas
Journal:  Wien Klin Wochenschr       Date:  2010-09-27       Impact factor: 1.704

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.